FY2022 EPS Estimates for Ascendis Pharma A/S (NASDAQ:ASND) Reduced by Analyst

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) – Equities researchers at Wedbush decreased their FY2022 earnings per share (EPS) estimates for Ascendis Pharma A/S in a research note issued to investors on Monday, November 14th. Wedbush analyst A. Argyrides now anticipates that the biotechnology company will post earnings of ($9.25) per share for the year, down from their previous forecast of ($8.98). Wedbush has a “Outperform” rating and a $164.00 price objective on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($9.06) per share. Wedbush also issued estimates for Ascendis Pharma A/S’s Q4 2022 earnings at ($2.42) EPS, Q1 2023 earnings at ($2.54) EPS, Q2 2023 earnings at ($2.47) EPS, Q3 2023 earnings at ($2.71) EPS, Q4 2023 earnings at ($2.66) EPS, FY2023 earnings at ($10.39) EPS, FY2024 earnings at ($10.77) EPS, FY2025 earnings at ($10.98) EPS and FY2026 earnings at ($10.30) EPS.

Several other equities research analysts have also recently weighed in on the company. Berenberg Bank reissued a “buy” rating and set a $166.00 price objective on shares of Ascendis Pharma A/S in a research note on Tuesday, August 30th. Credit Suisse Group boosted their price objective on Ascendis Pharma A/S from $123.00 to $130.00 and gave the stock an “outperform” rating in a research note on Thursday, November 3rd. Oppenheimer upped their target price on Ascendis Pharma A/S from $144.00 to $150.00 in a research note on Thursday, November 3rd. Cantor Fitzgerald cut their target price on Ascendis Pharma A/S from $184.00 to $182.00 in a research note on Thursday, October 27th. Finally, The Goldman Sachs Group initiated coverage on Ascendis Pharma A/S in a research note on Thursday, October 20th. They set a “buy” rating and a $174.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $159.55.

Ascendis Pharma A/S Trading Up 0.6 %

Shares of NASDAQ ASND opened at $115.58 on Thursday. The business’s 50 day moving average is $110.17 and its two-hundred day moving average is $96.75. The company has a debt-to-equity ratio of 1.18, a current ratio of 7.56 and a quick ratio of 6.83. Ascendis Pharma A/S has a 1-year low of $61.58 and a 1-year high of $158.05. The stock has a market capitalization of $6.59 billion, a P/E ratio of -12.55 and a beta of 0.55.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of large investors have recently made changes to their positions in ASND. Quadrant Capital Group LLC increased its position in shares of Ascendis Pharma A/S by 59.4% during the third quarter. Quadrant Capital Group LLC now owns 279 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 104 shares in the last quarter. Private Ocean LLC acquired a new position in shares of Ascendis Pharma A/S during the third quarter worth $49,000. Wipfli Financial Advisors LLC acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $53,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $54,000. Finally, BNP Paribas Arbitrage SA acquired a new position in shares of Ascendis Pharma A/S in the 2nd quarter valued at $67,000.

Ascendis Pharma A/S Company Profile

(Get Rating)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

Featured Stories

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.